A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

NCT07073417 · Active, not recruiting

Last updated 2026-05-28

This study is testing whether the investigational drug XW003, when given as an injection, helps reduce body weight in Chinese adults with obesity compared to the approved weight-loss drug semaglutide.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 163 people

Who can join Ages 18–75 · all sexes

Timeline Started 2025-07 · est. completion 2027-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07073417 ↗

Description as written by the study sponsor.

The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity

Treatments tested

XW003 injection also known as ecnoglutide Drug

Subcutaneous injection
semaglutide injection Drug

Subcutaneous injection

Main thing measured	Percentage change in body weight relative to baseline
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	Obesity, Weight Management
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07073417 ↗